Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: ADVANCED NON-SMALL CELL LUNG CANCER, . Treffer: 8
2022
Brcic, L; Savic, Prince, S
[Predictive immunocytochemistry in non-small cell lung carcinoma].
PATHOLOGE. 2022; 43(3): 222-228.
Doi: 10.1007/s00292-022-01066-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8):
Doi: 10.3390/cancers12082319
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Huemer, F; Lang, D; Westphal, T; Gampenrieder, SP; Hutarew, G; Weiss, L; Hackl, H; Lamprecht, B; Rinnerthaler, G; Greil, R
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
J Clin Med. 2019; 8(7):
Doi: 10.3390/jcm8071014
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Buder, A; Hochmair, MJ; Schwab, S; Bundalo, T; Schenk, P; Errhalt, P; Mikes, RE; Absenger, G; Patocka, K; Baumgartner, B; Setinek, U; Burghuber, OC; Prosch, H; Pirker, R; Filipits, M
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
J Thorac Oncol. 2018; 13(6):821-830
Doi: 10.1016/j.jtho.2018.02.014
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Huemer, F; Rinnerthaler, G; Westphal, T; Hackl, H; Hutarew, G; Gampenrieder, SP; Weiss, L; Greil, R
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.
Oncotarget. 2018; 9(23): 16512-16520.
Doi: 10.18632/oncotarget.24751
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
2014
Pircher, A; Manzl, C; Fiegl, M; Popper, H; Pirker, R; Hilbe, W
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Lung Cancer. 2014; 83(3): 408-410.
Doi: 10.1016/j.lungcan.2013.12.007
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
2011
Watzka, SB; Posch, F; Hochmair, M; Setinek, U; Köstler, WJ; Müller, MR
Resistance to EGFR targeting therapies in lung cancer.
Minerva Chir. 2011; 66(5): 483-494.
Web of Science
PubMed
2006
Pohl, G; Krajnik, G; Malayeri, R; Müller, RM; Klepetko, W; Eckersberger, F; Schäfer-Prokop, C; Pokrajac, B; Schmeikal, S; Maier, A; Ambrosch, G; Woltsche, M; Minar, W; Pirker, R
Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Lung Cancer. 2006; 54(1):63-67
Doi: 10.1016/j.lungcan.2006.05.027
Web of Science
PubMed
FullText
FullText_MUG